Overview Dividends

(RNA) Avidity Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US05370A1088

Antibody-Oligonucleotide, RNA-Therapeutics, Muscle-Dystrophy, Cardiomyopathy

Biotechnology
Market Cap in USD: 10,868m
IPO / Inception: 2013-06-28
Return 12m vs S&P 500: 95.6%

EPS (Earnings per Share)

EPS (Earnings per Share) of RNA over the last years for every Quarter: "2020-12": -0.43, "2021-03": -0.64, "2021-06": -0.7, "2021-09": -0.68, "2021-12": -0.82, "2022-03": -0.71, "2022-06": -0.92, "2022-09": -0.82, "2022-12": -0.88, "2023-03": -0.74, "2023-06": -0.66, "2023-09": -0.71, "2023-12": -0.79, "2024-03": -0.79, "2024-06": -0.65, "2024-09": -0.65, "2024-12": -0.8, "2025-03": -0.9, "2025-06": -1.21, "2025-09": -1.27,
EPS CAGR: -39.69%
EPS Trend: -41.7%
Last SUE: -1.06
Qual. Beats: 0

Revenue

Revenue of RNA over the last years for every Quarter: 2020-12: 2.142, 2021-03: 2.704, 2021-06: 2.607, 2021-09: 2.163, 2021-12: 1.852, 2022-03: 1.795, 2022-06: 2.178, 2022-09: 2.482, 2022-12: 2.769, 2023-03: 2.233, 2023-06: 2.316, 2023-09: 2.818, 2023-12: 2.193, 2024-03: 3.543, 2024-06: 2.045, 2024-09: 2.336, 2024-12: 2.973, 2025-03: 1.573, 2025-06: 3.847, 2025-09: 12.475,
Rev. CAGR: 66.31%
Rev. Trend: 47.6%
Last SUE: 4.00
Qual. Beats: 2

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 76.4%
Value at Risk 5%th 102%
Relative Tail Risk -18.86%
Reward TTM
Sharpe Ratio 1.44
Alpha 110.97
CAGR/Max DD 0.71
Character TTM
Hurst Exponent 0.399
Beta 1.066
Beta Downside 0.838
Drawdowns 3y
Max DD 81.01%
Mean DD 31.57%
Median DD 34.33%

Description: RNA Avidity Biosciences November 07, 2025

Avidity Biosciences (NASDAQ:RNA) is a San-Diego-based biopharma that develops antibody-oligonucleotide conjugates (AOCs), marrying monoclonal-antibody targeting with RNA-based gene-silencing to reach disease mechanisms that conventional biologics cannot.

Its current pipeline includes three registrational-stage programs: Delpacibart etedesiran (Phase 3 for myotonic dystrophy type 1), Delpacibart braxlosiran (Phase 1/2 for facioscapulohumeral muscular dystrophy) and Delpacibart zotadirsen (Phase 2 EXPLORE44 open-label extension for Duchenne muscular dystrophy). In addition, Avidity is advancing precision-cardiology AOCs such as AOC 1086 for phospholamban cardiomyopathy and AOC 1072 for PRKAG2-related cardiomyopathy.

As of Q3 2024, the company reported cash and equivalents of roughly $210 million, giving it an estimated 12-month runway at current burn rates (~$20 million per quarter). The RNA-therapeutics market is projected to grow at a 10-12% CAGR through 2030, driven by expanding FDA approvals for oligonucleotide drugs and increasing payer acceptance of rare-disease therapies-factors that could lift Avidity’s valuation if its Phase 3 readout is positive.

For a deeper, data-driven look at RNA’s risk-adjusted upside, you might explore the analyst tools on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-549.8m TTM) > 0 and > 6% of Revenue (6% = 1.25m TTM)
FCFTA -0.28 (>2.0%) and ΔFCFTA -16.41pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 8607 % (prev 15.1k%; Δ -6521 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.27 (>3.0%) and CFO -580.5m <= Net Income -549.8m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 11.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (137.9m) change vs 12m ago 11.77% (target <= -2.0% for YES)
Gross Margin -565.4% (prev 73.78%; Δ -639.2pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 1.11% (prev 0.62%; Δ 0.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -12.38 (EBITDA TTM -594.7m / Interest Expense TTM -48.3m) >= 6 (WARN >= 3)

Altman Z'' -4.33

(A) 0.84 = (Total Current Assets 1.97b - Total Current Liabilities 169.9m) / Total Assets 2.13b
(B) -0.63 = Retained Earnings (Balance) -1.34b / Total Assets 2.13b
(C) -0.32 = EBIT TTM -598.1m / Avg Total Assets 1.89b
(D) -5.40 = Book Value of Equity -1.34b / Total Liabilities 247.9m
Total Rating: -4.33 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 33.00

1. Piotroski 0.0pt
2. FCF Yield -6.58%
3. FCF Margin data missing
4. Debt/Equity 0.03
5. Debt/Ebitda 0.50
6. ROIC - WACC (= -42.30)%
7. RoE -37.70%
8. Rev. Trend 47.56%
9. EPS Trend -41.65%

What is the price of RNA shares?

As of January 07, 2026, the stock is trading at USD 72.25 with a total of 2,767,002 shares traded.
Over the past week, the price has changed by +0.14%, over one month by +1.39%, over three months by +56.45% and over the past year by +129.95%.

Is RNA a buy, sell or hold?

Avidity Biosciences has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy RNA.
  • Strong Buy: 9
  • Buy: 6
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the RNA price?

Issuer Target Up/Down from current
Wallstreet Target Price 74.6 3.3%
Analysts Target Price 74.6 3.3%
ValueRay Target Price 95 31.4%

RNA Fundamental Data Overview January 03, 2026

Market Cap USD = 10.87b (10.87b USD * 1.0 USD.USD)
P/S = 520.809
P/B = 5.7618
Beta = 0.905
Revenue TTM = 20.9m USD
EBIT TTM = -598.1m USD
EBITDA TTM = -594.7m USD
Long Term Debt = 50.0m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.97m USD (from shortTermDebt, last quarter)
Debt = 50.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -300.2m USD (from netDebt column, last quarter)
Enterprise Value = 9.04b USD (10.87b + Debt 50.0m - CCE 1.88b)
Interest Coverage Ratio = -12.38 (Ebit TTM -598.1m / Interest Expense TTM -48.3m)
FCF Yield = -6.58% (FCF TTM -595.4m / Enterprise Value 9.04b)
FCF Margin = -2853 % (FCF TTM -595.4m / Revenue TTM 20.9m)
Net Margin = -2635 % (Net Income TTM -549.8m / Revenue TTM 20.9m)
Gross Margin = -565.4% ((Revenue TTM 20.9m - Cost of Revenue TTM 138.9m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev -3490 %)
Tobins Q-Ratio = 4.24 (Enterprise Value 9.04b / Total Assets 2.13b)
Interest Expense / Debt = 0.78% (Interest Expense 391.0k / Debt 50.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = -472.5m (EBIT -598.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 11.57 (Total Current Assets 1.97b / Total Current Liabilities 169.9m)
Debt / Equity = 0.03 (Debt 50.0m / totalStockholderEquity, last quarter 1.89b)
Debt / EBITDA = 0.50 (negative EBITDA) (Net Debt -300.2m / EBITDA -594.7m)
Debt / FCF = 0.50 (negative FCF - burning cash) (Net Debt -300.2m / FCF TTM -595.4m)
Total Stockholder Equity = 1.46b (last 4 quarters mean from totalStockholderEquity)
RoA = -25.76% (Net Income -549.8m / Total Assets 2.13b)
RoE = -37.70% (Net Income TTM -549.8m / Total Stockholder Equity 1.46b)
RoCE = -39.66% (EBIT -598.1m / Capital Employed (Equity 1.46b + L.T.Debt 50.0m))
RoIC = -32.40% (negative operating profit) (NOPAT -472.5m / Invested Capital 1.46b)
WACC = 9.90% (E(10.87b)/V(10.92b) * Re(9.94%) + D(50.0m)/V(10.92b) * Rd(0.78%) * (1-Tc(0.21)))
Discount Rate = 9.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 34.65%
Fair Price DCF = unknown (Cash Flow -595.4m)
EPS Correlation: -41.65 | EPS CAGR: -39.69% | SUE: -1.06 | # QB: 0
Revenue Correlation: 47.56 | Revenue CAGR: 66.31% | SUE: 4.0 | # QB: 2
EPS next Quarter (2026-03-31): EPS=-1.28 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=8
EPS next Year (2026-12-31): EPS=-4.89 | Chg30d=+0.005 | Revisions Net=-1 | Growth EPS=-8.9% | Growth Revenue=+5.3%

Additional Sources for RNA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle